Meet Our Team
The Sygnature leadership team embodies a dynamic fusion of backgrounds, experiences, and expertise. Their collective synergy is the driving force behind Sygnature’s success in drug discovery.
The Sygnature leadership team embodies a dynamic fusion of backgrounds, experiences, and expertise. Their collective synergy is the driving force behind Sygnature’s success in drug discovery.
Filter by:
Dr Simon Hirst
Chief Executive Officer
Amira Modi
Chief Operating Officer
Dr Jonathan Williams
Chief Resilience Officer
Dr David Witty
Chief Scientific Officer
Louisa Jordison
Chief Financial Officer
James Edgar
Chief People Officer
Dr Stuart Onions
Chief Technical Officer
Dr Allan Jordan
Vice President of Oncology Drug Discovery
Dr John Unitt
Vice President, Immunology and Inflammation Drug Discovery
Dr Max Mirza
Vice President, Neuroscience Drug Discovery
Dr Stephen Young
VP Hit ID Technologies
Dr Emily Eaton
VP Commercial Services
Dr Geraint Jones
Director of Chemistry
Colin Sambrook Smith
Director of Computational Sciences and Informatics
Jane Kendrew
Director of Translational Oncology
Dr Dave Pearson
Director of Form and Formulation
Dr Alex Stevens
Director of DMPK
Who We Are
Sygnature Discovery prides itself on offering a unique, high-quality, distinctive and tailored integrated drug discovery service to our clients. Our mission is to be admired for the science we do,…
Working with Us
[embed]https://www.youtube.com/watch?v=hSEDjMTjWYg[/embed] No two projects will ever be the same, but there are commonly recurring challenges that hinder progress towards a strong candidate molecule. Sygnature draws on the past experience of…
Company History
Since 2004 Sygnature Discovery has been offering high-quality drug discovery services and providing guidance and support to customers for the discovery and development of novel medicines. We have grown significantly…